Personalised Cancer Plan
Make treatment decisions with greater confidence
Precision insights that complement standard oncology care to support next-step planning, biomarker evaluation, and ongoing monitoring discussions with your healthcare team.
Precision-guided personalised plans have been studied across multiple published settings — including associations with tumour response, time without progression, and outcomes in certain high-risk or hard-to-treat cancers.
Personalised Cancer
Care May Influence
Outcomes
approach
approach
approach
approach
2. Sources: Von Hoff et al., 2010; Tsimberidou et al., 2014; Mosse et al., 2020.
Studies in advanced and paediatric cancers evaluating matched (biomarker-guided) versus non-matched approaches.
Key Studies and What They Are About
Selected published studies and institutional references related to precision oncology, molecular profiling, liquid biopsy, and biomarker-guided treatment approaches.
Tsimberidou et al.
About: Personalized medicine outcomes in patients with advanced cancer treated in the MD Anderson phase I program.
Findings: Matched treatment approaches were reported alongside differences in clinical outcomes in this cohort.
Von Hoff et al.
About: Molecular profiling used to help select therapy in previously treated metastatic cancer.
Findings: Tumour profiling was explored as a way to support treatment selection in selected refractory cases.
Key Studies and What They Are About
A visual overview of the studies, reports, and institutional references related to precision oncology, molecular profiling, circulating tumor biology, and matched treatment approaches.
Tsimberidou et al.
Journal of Clinical Oncology
About: Personalized medicine outcomes in patients with advanced cancer treated in the MD Anderson phase I program.
Von Hoff et al.
Journal of Clinical Oncology
About: Molecular profiling used to help select therapy in previously treated metastatic cancer.
Alix-Panabières & Pantel
Nature Reviews Clinical Oncology
About: Clinical relevance of circulating tumor cells and circulating tumor DNA.
Herzog et al.
Gynecologic Oncology
About: ChemoID-guided therapy in platinum-resistant ovarian cancer.
Lindeman et al.
Journal of Thoracic Oncology
About: Updated molecular testing guideline for lung cancer.
Ross et al.
Cancer
About: Comprehensive genomic profiling in lung cancer.
MD Anderson Cancer Center
Program overview
About: IMPACT study and precision medicine program outcomes in advanced cancer.
MD Anderson Cancer Center
Program reference
About: Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT).
UC San Diego Moores Cancer Center
PREDICT study
About: Molecular profiling and clinical outcomes.
UC San Diego Moores Cancer Center
Institutional real-world data
About: Molecular tumor board real-world data in breast and gynecologic cancers.
National Cancer Institute
Pediatric MATCH trial
About: Molecular Analysis for Therapy Choice in pediatric cancer.
Precision oncology survival outcomes
Summary report
About: Survival outcomes in late-stage cancer patients.
Precision medicine in lung cancer
Summary report
About: Clinical benefit analysis in lung cancer.
Impact of precision medicine on clinical outcomes
Summary report
About: How precision medicine may influence clinical outcomes.
Book a 15-Minute Consultation with our Cancer Professionals
This consultation will help you understand how precision medicine may support your treatment journey.
Contact Us
Contact Us for the updated information on Precision Medicine
+852 4750 3485
Email Us
info@mycancerinfo.org